- POSITIVE
Quarterly Revenue Senores Pharmaceuticals Sep-2026 Quarterly Revenue is Rs 50 Cr which is growth of 8.0% YoY.
- POSITIVE
Quarterly Net Profit Senores Pharmaceuticals Sep-2026 Quarterly Net Profit is Rs 8 Cr which is growth of 20.1% YoY.
1090.80-22.10(-1.99%)
250.3K
NSE+BSE Volume
NSE 20 Nov, 2026 3:31 PM
Senores Pharmaceuticals quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Forecaster Analyst Estimates for Senores Pharmaceuticals share price target, revenues, EPS, net income and more
Senores Pharmaceuticals quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.4 | 36.5 | 59 | 38.5 | 46.7 | 28.2 | 21.1 | 16.8 | 12.7 | 9.9 | 40.9 | 11.1 | ||
Operating Exp. | 34.6 | 29.3 | 40.3 | 29.7 | 33.8 | 21 | 14.6 | 12 | 11 | 8.3 | 34.1 | 9.4 | |
Operating Profit | 1.1 | -2.3 | -3.5 | -0.9 | 1.5 | -1.2 | -2.7 | -2.4 | -1.3 | -0.8 | -0.1 | -0.5 | |
Operating Profit Margin % | 2.97% | -8.63% | -9.45% | -3.23% | 4.30% | -5.80% | -23.10% | -25.23% | -13.91% | -10.29% | -0.18% | -5.95% | |
Depr. | 3.9 | 3.6 | 4.1 | 3.6 | 3.7 | 1.9 | 1.3 | 0.8 | 0.5 | 0.5 | 2 | 0.5 | |
Interest | 2.2 | 2.2 | 1.9 | 1.8 | 1.6 | 1.8 | 2.4 | 2.7 | 0.7 | 0.8 | 2.7 | 0.7 | |
Profit Before Tax | 9.7 | 1.4 | 12.7 | 3.5 | 7.7 | 3.6 | 2.9 | 1.3 | 0.5 | 0.4 | 2 | 0.5 | |
Tax | 2 | 0.4 | 4.2 | 0.9 | 1.2 | 0.9 | 0.9 | 0.3 | 0.2 | 0.1 | 1.2 | 0.3 | |
Net Profit | 7.7 | 1 | 8.5 | 2.7 | 6.4 | 2.7 | 2 | 1.1 | 0.3 | 0.3 | 0.8 | 0.2 | |
EPS Adj. latest | 1.7 | 0.2 | 1.8 | 0.6 | 1.4 | 0.6 | 0.4 | 0.2 | 0.1 | 0.1 | 0.2 | 0 | |
Net profit TTM | 19.9 | 18.6 | 20.3 | 13.8 | 12.2 | 6.1 | 3.7 | 2.5 | 1.6 | - | - | - | |
Basic EPS TTM | 4.3 | 4 | 4.4 | 3 | 2.7 | 1.3 | 0.8 | 0.5 | 0.5 | - | - | - | |
Earnings Transcripts | |||||||||||||
AI Summary | |||||||||||||
Results PDF | |||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Senores Pharmaceuticals competitor comparison and performance snapshot within industry
Senores Pharmaceuticals annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue Senores Pharmaceuticals Mar-2026 Annual Revenue is Rs 172 Cr which is growth of 184.9% YoY.
- POSITIVE
Annual Net Profit Senores Pharmaceuticals Mar-2026 Annual Net Profit is Rs 20 Cr which is growth of 448.8% YoY.
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
185%
2Y CAGR
105.3%
3Y CAGR
107.8%
5Y CAGR
84.3%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
448.6%
2Y CAGR
403.7%
3Y CAGR
156.7%
5Y CAGR
90.9%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
172.5%
2Y CAGR
91.3%
3Y CAGR
106.4%
5Y CAGR
78.4%
Operating Expenses Annual Cr growth is higher than historical averages.
Senores Pharmaceuticals balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund Senores Pharmaceuticals Mar-2026 Total Shareholders Fund is Rs 750 Cr which is growth of 5.9% YoY.
- POSITIVE
Total Assets Senores Pharmaceuticals Mar-2026 Total Assets is Rs 888 Cr which is growth of 6.5% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
168.1% | 139.6% | 749.9 | 708 | 168.1 | 38.9 | 33.8 | 9.5 | ||
Minority Interest Liability Ann. | - | - | - | - | - | - | - | - | |
38.1% | 84.5% | 68.5 | 84.9 | 27.1 | 26 | 2.2 | 3.2 | ||
14.1% | 97.8% | 69.6 | 41.2 | 90.7 | 46.8 | 18.8 | 2.3 | ||
Total Capital Plus Liabilities Ann. | 99.6% | 126.2% | 887.9 | 834.1 | 285.9 | 111.7 | 54.7 | 15 | |
79.4% | 90.4% | 110.2 | 88.6 | 42.6 | 19.1 | 4.3 | 4.4 | ||
96% | 147.6% | 632.3 | 422 | 245.9 | 84 | 39.5 | 6.8 | ||
109.7% | 99% | 255.6 | 412.1 | 40 | 27.7 | 15.2 | 8.2 | ||
Total Assets Ann. | 99.6% | 126.2% | 887.9 | 834.1 | 285.9 | 111.7 | 54.7 | 15 | |
Contingent Liabilities plus Commitments Ann. | - | 359.4% | 204.7 | 172 | 23.3 | 0.1 | 0.1 | ||
Bonus Equity Share Capital Ann. | - | - | |||||||
Non Current Investments Unquoted Book Value Ann. | 166.1% | - | 154.5 | 104.4 | 81.6 | 8.2 | 0 | ||
Current Investments Unquoted Book Value Ann. | - | - |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Assets Ann.
1Y CHG
6.5%
2Y CAGR
76.2%
3Y CAGR
99.6%
5Y CAGR
126.2%
Total Assets Annual growth is lower than historical averages.
Total Current Liabilities Ann.
1Y CHG
68.9%
2Y CAGR
-12.4%
3Y CAGR
14.1%
5Y CAGR
97.8%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
5.9%
2Y CAGR
111.2%
3Y CAGR
168.1%
5Y CAGR
139.6%
Total ShareHolders Funds Annual growth is lower than historical averages.
Senores Pharmaceuticals ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Book Value Per Share Senores Pharmaceuticals Mar-2026 Book Value Per Share is 163 Rs which is growth of 5.9% YoY.
- POSITIVE
ROE Senores Pharmaceuticals Mar-2026 ROE is 3% which is growth of 2.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
BVSH Ann. | 60.1% | 45.6% | 162.8 | 153.7 | 55.1 | 39.7 | 38.6 | 24.9 | |
RoA Ann. % | 28.7% | -16.4% | 2.28% | 0.44% | 0.28% | 1.07% | 0.53% | 5.58% | |
ROE Ann. % | -4.3% | -21.1% | 2.70% | 0.52% | 0.48% | 3.08% | 0.86% | 8.83% | |
ROCE Ann. % | -12.5% | -2.3% | 4.20% | 1.46% | 2.43% | 6.28% | 3.89% | 4.73% | |
Total Debt to Total Equity Ann. | -60.3% | -24.2% | 0.1 | 0.1 | 0.6 | 1.6 | 0.4 | 0.4 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
ROE Ann. %
1Y CHG
419.2%
2Y CAGR
137.2%
3Y CAGR
-4.3%
5Y CAGR
-21.1%
ROE Annual % is growing faster than historical averages.
RoA Ann. %
1Y CHG
418.2%
2Y CAGR
185.4%
3Y CAGR
28.7%
5Y CAGR
-16.4%
RoA Annual % is growing faster than historical averages.
Current Ratio Ann.
1Y CHG
-63%
2Y CAGR
204.1%
3Y CAGR
83.4%
5Y CAGR
0.5%
Current Ratio Annual is falling faster than historical averages.
Senores Pharmaceuticals cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity Senores Pharmaceuticals Mar-2026 Cash From Operating Activity is Rs -27 Cr which is growth of -31.8% YoY.
- NEGATIVE
Net Cash Flow Senores Pharmaceuticals Mar-2026 Net Cash Flow is Rs -49 Cr which is growth of -114.0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
- | - | -26.9 | -20.4 | -62.8 | -43.4 | -12.2 | -2.9 | ||
Cash from Investing Act. Ann. | - | - | -19.5 | -162.9 | -13.5 | -5.2 | -11.3 | -4.4 | |
Cash from Financing Act. Ann. | - | - | -2.6 | 532.6 | 86.7 | 47.1 | 23.4 | 8.5 | |
- | - | -49 | 349.3 | 10.4 | -1.6 | -0.1 | 1.3 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
